Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?

PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).

Source link
#Risk #adjusted #net #present #current #valuation #Johnson #amp #Johnsons #PN235